Hardman & Co Research
Hardman & Co Research: Preparing for commercialisation
Advanced Oncotherapy's (AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of technical milestones, the successful integration of all the module types that constitute the LIGHT accelerator, and the acceleration of the proton beam to an energy of 52MeV, sufficient to treat superficial tumours. Meanwhile, AVO has started to gear up its commercial infrastructure through the recruitment of a Chief Commercial Officer (CCO) with experience in PBT solutions. Please click here for the full report:
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
Aktien in diesem Artikel
|Advanced Oncotherapy PLC||0,54||-6,87%|
Nachrichten zu Advanced Oncotherapy PLC
|Advanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth (EQS Group)||16.05.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology (EQS Group)||13.05.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation (EQS Group)||16.04.19|
|Advanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT (EQS Group)||16.04.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval (EQS Group)||21.01.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated (EQS Group)||16.10.18|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement (EQS Group)||16.10.18|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement (EQS Group)||03.09.18|